{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:10:41Z","timestamp":1759342241423,"version":"3.37.3"},"reference-count":43,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2017,1,23]],"date-time":"2017-01-23T00:00:00Z","timestamp":1485129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Treatment of hepatitis C virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>) infection with genotype 3 remains a challenge. The <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> elimination rate with direct\u2010acting antivirals (<jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>s) is lower than the values reported for other <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotypes. In addition, genotype 3\u2010infected patients have a higher risk of disease progression and hepatocellular carcinoma. The aim of this study was to review the relevant literature concerning the treatment of <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype 3 patients with interferon\u2010free regimens. A literature search was conducted in the PubMed\/Medline, Embase and Web of Science electronic databases. Trials enrolling patients with chronic hepatitis C infection treated with <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>s with or without ribavirin were included. Two investigators independently evaluated the trials for inclusion criteria, risk of bias and data extraction. The primary outcome was sustained virological response (<jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>). In total, 323 references were identified, and 29 met the inclusion criteria: 18 general clinical trials, three general observational studies, three studies in patients with decompensated liver cirrhosis and four studies in <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u2013<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\u2010coinfected patients. Overall, 4068 genotype 3 patients were included. As compared with sofosbuvir and ribavirin for 24\u00a0weeks, sofosbuvir\/velpatasvir for 12\u00a0weeks or sofosbuvir plus daclatasvir plus ribavirin for 12 weeks provided higher <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> rates, particularly in patients with cirrhosis. Treatment of patients with decompensated cirrhosis remains a great challenge. Sofosbuvir\/ledipasvir+ribavirin for 12 weeks were associated with an <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> of 85% in these patients. In summary, treatment of <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype 3 patients is improving rapidly, and this population may no longer be considered a difficult\u2010to\u2010treat subgroup in the near future.<\/jats:p>","DOI":"10.1111\/jvh.12660","type":"journal-article","created":{"date-parts":[[2016,12,7]],"date-time":"2016-12-07T12:53:41Z","timestamp":1481115221000},"page":"904-916","source":"Crossref","is-referenced-by-count":8,"title":["Interferon\u2010free therapies for patients with chronic hepatitis C genotype 3 infection: A systematic review"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9066-7903","authenticated-orcid":false,"given":"V.","family":"Gimeno\u2010Ballester","sequence":"first","affiliation":[{"name":"Department of Pharmacy Hospital Universitario Miguel Servet  Zaragoza Spain"},{"name":"Faculty of Pharmacy University of Granada  Granada Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Buti","sequence":"additional","affiliation":[{"name":"Liver Unit Hospital Universitario Valle Hebron and Ciberehd del Intituto Carlos III  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"San Miguel","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy University of Granada  Granada Spain"},{"name":"Department of Pharmacy Complejo Hospitalario de Navarra  Pamplona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Riveiro","sequence":"additional","affiliation":[{"name":"Liver Unit Hospital Universitario Valle Hebron and Ciberehd del Intituto Carlos III  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Esteban","sequence":"additional","affiliation":[{"name":"Liver Unit Hospital Universitario Valle Hebron and Ciberehd del Intituto Carlos III  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,1,23]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.027"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.05.016"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27095"},{"key":"e_1_2_7_5_1","unstructured":"European Medicines Agency.Epclusa [Internet]. Product Information.2016.http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/004210\/human_med_001997.jsp&mid=WC0b01ac058001d124. Cited 2016 September 26."},{"key":"e_1_2_7_6_1","unstructured":"European Medicines Agency.Harvoni [Internet]. Product Information.2016.http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003850\/human_med_001813.jsp&mid=WC0b01ac058001d124. Cited 2016 September 26."},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"e_1_2_7_8_1","unstructured":"Mendeley: Free reference manager and PDF organizer [Internet].2016.http:\/\/www.mendeley.com\/. Cited 2016 June 4."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2008.12.010"},{"key":"e_1_2_7_11_1","unstructured":"PhillipsB BallC SackettD BadenochD StrausS HaynesB et\u00a0al.Oxford centre for evidence\u2010based medicine levels of evidence [Internet]. 2001 [cited 2016 Aug 24]. Available from:http:\/\/www.cebm.net\/oxford-centre-evidence-based-medicine-levels-evidence-march-2009\/"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214854"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316145"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.07.043"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw387"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.05.049"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27726"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28473"},{"key":"e_1_2_7_20_1","first-page":"314A","article-title":"Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program","volume":"62","author":"Hezode C","year":"2015","journal-title":"Hepatology"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(16)01523-3"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.07.063"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-1000"},{"key":"e_1_2_7_24_1","first-page":"236A","article-title":"Once daily sofosbuvir with GS\u20105816 for 8 weeks with or without ribavirin in patients with HCV genotype 3 without cirrhosis result in high rates of SVR12: the ELECTRON2 study","volume":"60","author":"Gane EJ","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-1014"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512612"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512614"},{"key":"e_1_2_7_28_1","first-page":"225A","article-title":"Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: Interim results of a multicenter European compassionate use program","volume":"62","author":"Welzel TM","year":"2015","journal-title":"Hepatology"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312444"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.01.029"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7734"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62483-1"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(16)00129-X"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503153"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13067"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2014.09.008"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30013-1"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.07.038"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.05.021"},{"volume-title":"HEPDART 2015: Frontiers in Drug Development for Viral Hepatitis","author":"Kwo P","key":"e_1_2_7_40_1"},{"key":"e_1_2_7_41_1","doi-asserted-by":"crossref","unstructured":"MuirAJ StrasserS WangS et\u00a0al.High SVR rates with ABT\u2010493 + ABT\u2010530 co\u2010administered for 8 weeks in non\u2010cirrhotic patients with HCV genotype 3 infection. In: 51st EASL;Barcelona Spain; April 13\u201017 2016.2016.","DOI":"10.1016\/S0168-8278(16)01700-1"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.07.020"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27950"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.08.004"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12660","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12660","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T17:03:25Z","timestamp":1695575005000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,23]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1111\/jvh.12660"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12660","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"type":"print","value":"1352-0504"},{"type":"electronic","value":"1365-2893"}],"subject":[],"published":{"date-parts":[[2017,1,23]]}}}